Share on StockTwits

Inovio Pharmaceuticals (NYSE:INO) announced its earnings results on Monday. The company reported ($0.18) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.19) by $0.01, American Banking and Market News reports. The company had revenue of $3.80 million for the quarter, compared to the consensus estimate of $1.80 million.

Several analysts have recently commented on the stock. Analysts at Aegis upgraded shares of Inovio Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, July 24th. They now have a $19.00 price target on the stock, up previously from $10.00. Four investment analysts have rated the stock with a buy rating, Inovio Pharmaceuticals currently has an average rating of “Buy” and a consensus target price of $20.20.

Shares of Inovio Pharmaceuticals (NYSE:INO) opened at 9.82 on Monday. Inovio Pharmaceuticals has a 52-week low of $4.88 and a 52-week high of $15.80. The stock has a 50-day moving average of $10.44 and a 200-day moving average of $10.88. The company’s market cap is $590.7 million.

Inovio Pharmaceuticals, Inc is engaged in the development of a new generation of vaccines, called synthetic vaccines, focused on cancers and infectious diseases.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.